United States: Food, Drugs, Healthcare, Life Sciences

On May 18, the Supreme Court denied all six petitions for certiorari filed by drug manufacturers challenging the IRA’s Medicare Drug Price Negotiation Program, bringing much of the first wave of constitutional challenges to a close.

Alexander G. Malyshev and Sarah H. Ganley examine the final order rescheduling cannabis from Schedule I to Schedule III of the Controlled Substances Act. The analysis clarifies that this rescheduling applies specifically to medical cannabis and does not constitute federal legalization of cannabis.

A California federal court dismissed a class action lawsuit challenging Carnation Breakfast Essentials' labeling, ruling that emphasizing protein content while disclosing sugar levels on the Nutrition Facts panel does not...

Welcome to FDA in Flux – A Mintz newsletter tracking rapid changes in policy and agency actions that impact medical, life sciences, and consumer product investment decisions and development strategies.

Today’s drug development programs routinely span continents: distributed research teams, multinational clinical trial networks, and complex webs of cross-border licensing, contract manufacturing...

Partner Jason Schultz explores the evolving role of in-house counsel in healthcare organizations, identifying five critical capabilities that legal professionals must develop to remain effective strategic partners. The article examines how modern healthcare lawyers can enhance their value by mastering skills beyond traditional legal expertise, including project management, emotional intelligence, and business acumen.

On May 18, the Supreme Court denied all six petitions for certiorari filed by drug manufacturers challenging the IRA’s Medicare Drug Price Negotiation Program, bringing much of the first wave of constitutional challenges to a close.

CMS has issued nationwide moratoria on new Medicare enrollments for hospices and home health agencies, effective May 13, 2026, halting all new applications and branch expansions for at least six months.

The Supreme Court of the United States temporarily reinstated the ability of patients to receive mifepristone via mail-order after a telehealth visit following a recent decision by the U.S. Court of Appeals for the Fifth Circuit staying implementation of guidelines previously adopted by the FDA that eliminated in-person physician consultation and dispensing requirements for the drug.